Journal ArticleDOI
Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.Abstract:
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.read more
Citations
More filters
Patent
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
Wolfgang A. Renner,Martin F. Bachmann,Indulis Cielens,Conrad Coester,Klaus Dietmeier,Sebastian Fuchs,Vania Manolova,Patrik Maurer,Paul Pumpens,Regina Renhofa,Alain Tissot,Yu Zou +11 more
TL;DR: In this paper, the compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
Journal ArticleDOI
PLGA Nanoparticles for the Oral Delivery of 5-Fluorouracil Using High Pressure Homogenization-Emulsification as the Preparation Method and In Vitro/In Vivo Studies
TL;DR: It is possible to design a controlled drug delivery system for oral 5-FU delivery, improving therapy efficiency by possible reduction of time intervals between peroral administrations and reduction of local gastrointestinal side effects.
Patent
Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same
TL;DR: The present disclosure generally relates to therapeutic nanoparticles as mentioned in this paper, which may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer.
Journal ArticleDOI
Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.
Maofan Zhang,Maofan Zhang,C. Tilden Hagan,Yuangzeng Min,Hayley Foley,Xi Tian,Feifei Yang,Feifei Yang,Yu Mi,Kin Man Au,Yusra Medik,Kyle C. Roche,Kyle Wagner,Zachary L. Rodgers,Zachary L. Rodgers,Andrew Z. Wang +15 more
TL;DR: NP co-delivery of cisplatin (CP) and wortmannin (Wtmn), a DNA repair inhibitor, synergistically enhances chemoradiotherapy (CRT) and reverses CP resistance in PROC, and results support further investigation of this NP-based, synergistic drug regimen as a means to combat PROC in the clinic.
Journal ArticleDOI
Amphiphilic PEG/alkyl-grafted comb polylactides
TL;DR: In this paper, a ring-opening polymerization of AB monomers (glycolides) substituted with both a long chain alkyl group and a triethylene glycol segment terminated in either a methyl or benzyl group was used to synthesize amphiphilic polylactides.